Papers
11
Total Citations
509
H-Index
9
About
Andrew G. Sikora is a leading head and neck surgical oncologist whose research has fundamentally reshaped the treatment of oropharyngeal cancer, particularly by advancing transoral robotic surgery (TORS) as a precise, minimally invasive alternative to chemoradiation. His work focuses on optimizing oncologic outcomes while dramatically reducing treatment toxicity. Sikora’s landmark 2011 study on TORS resection and reconstruction (163 citations) established the procedure’s safety and efficacy, while his cost-effectiveness analysis (100 citations) provided the economic rationale for its adoption over chemoradiotherapy. He spearheaded the pivotal Sinai Robotic Surgery (SIRS) trial (62 citations), demonstrating that de-escalated adjuvant therapy after TORS can preserve excellent survival rates while minimizing unnecessary side effects for patients with HPV-related disease. Beyond surgical technique, Sikora has pioneered novel immunotherapy approaches, including a first-in-human trial of an HPV E7-targeting *Listeria*-based vaccine (ADXS11-001) administered before robotic surgery to enhance antitumor T-cell immunity. His research also integrates advanced intraoperative imaging to improve margin assessment. With over 500 cumulative citations, Sikora’s work has defined a new standard for function-preserving, personalized treatment in head and neck oncology.
Research Focus
Key Achievements
Top Papers
- 1Transoral robotic resection and reconstruction for head and neck cancer163 citations · 2011
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10